ArticleJournal of clinical imaging science2026
Follow-up after an abnormal screening mammogram: Impact of a pandemic on mobile mammography patients.
Article in Journal of clinical imaging science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Objectives: To evaluate the effect of COVID-19 on a mobile screening mammography program as measured by turnaround time (TAT) in days between an abnormal screening mammogram (sMG) and diagnostic mammography. Material and Methods: All of our institution's sMG (mobile and non-mobile) from January 2017, to December 2022 were retrospectively reviewed, and those dated March 7, 2020-July 7, 2020 were excluded because our mobile sMG program was non-operative at that time due to COVID-19. TATs and patient demographics were compared for mobile and non-mobile sMG patients between 2 time periods: Pre-pandemic (January 1, 2017-March 6, 2020) and pandemic (July 8, 2020-December 31, 2022). Statistics included multiple linear regression analysis, Fisher's Exact, and Wilcoxon Rank Sum tests. Results: During the pre-pandemic period, 11,439 female patients (9309 without insurance, 81.3%) underwent 14,161 mobile sMG, while 28,737 female patients (429 without insurance, 1.5%) underwent 57,840 non-mobile sMG. During the pandemic period, 6805 female patients (6720 without insurance, 98.8%) underwent 7663 mobile sMG, while 32,655 female patients (868 without insurance, 2.7%) underwent 53,540 non-mobile sMG. Median TATs for mobile uninsured patients increased from 41 days during the pre-pandemic period to 51 days during the pandemic period ( Conclusion: For mobile uninsured screening patients, the number of days between screening and diagnostic mammography increased with the COVID-19 pandemic, while it decreased for non-mobile insured screening patients. Mobile uninsured mammography patients may represent a population that needs additional attention. These findings highlight a health equity concern, as the pandemic disproportionately widened disparities in timely follow-up care for uninsured patients served by mobile mammography programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.